A novel promising therapeutic option against hepatitis C Virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir

Current Medicinal Chemistry

Volumn 20, Issue 30, 2013, Pages 3733-3742

  Gentile, I ^a   Borgia, F ^a,b   Buonomo, A R ^a   Castaldo, G ^a,b   Borgia, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Clinical trial; Combination therapy; Hepatitis C virus; Pegylated interferon; Polymerase inhibitors; Resistance; Ribavirin; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; PEGINTERFERON ALPHA; PLACEBO; PSI 938; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BACKACHE; DIZZINESS; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; INSOMNIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; RASH; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84883404339     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990178     Document Type: Article

References (38)

1. Lavanchy, D. The global burden of hepatitis C. Liver Int., 2009, 1, 74-81.
2. Gentile, I.; Di Flumeri, G.; Scarica, S.; Frangiosa, A.; Foggia, M.; Reynaud, L.; Borgia, G. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol. Nefrol., 2013, 65(1), 83-84.
3. Hoofnagle, J. H. Hepatitis C: the clinical spectrum of disease. Hepatology, 1997, 26(3 Suppl 1), 15S-20S.
4. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol., 2004, 44 (1), 20-29.
5. Menzin, J.; White, L. A.; Nichols, C.; Deniz, B. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv. Res., 2012, 12(459), 1472-6963.
6. Ghany, M. G.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 2009, 49(4), 1335-1374.
7. Coppola, N.; Pisaturo, M.; Tonziello, G.; Sagnelli, C.; Sagnelli, E.; Angelillo, I. F. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect. Dis., 2012, 12(357), 1471-2334.
8. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y. T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K. C.; Hsieh, Y.; Brisson, J. M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-amino-1- (cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem., 2006, 49(20), 6074-6086.
9. Tong, X.; Chase, R.; Skelton, A.; Chen, T.; Wright-Minogue, J.; Malcolm, B. A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res., 2006, 70(2), 28-38.
10. Lin, C.; Kwong, A. D.; Perni, R. B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets, 2006, 6(1), 3-16.
11. Ghany, M. G.; Nelson, D. R.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011, 54(4), 1433-1444.
12. Braks, R. E.; Ganne-Carrie, N.; Fontaine, H.; Paries, J.; Grando-Lemaire, V.; Beaugrand, M.; Pol, S.; Trinchet, J. C. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J. Gastroenterol., 2007, 13(42), 5648-5653.
13. Tsuda, N.; Yuki, N.; Mochizuki, K.; Nagaoka, T.; Yamashiro, M.; Omura, M.; Hikiji, K.; Kato, M. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol., 2004, 74(3), 406-413.
14. Gentile, I.; Borgia, G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J. Hepatol., 2010, 52(5), 778.
15. Bruno, S.; Stroffolini, T.; Colombo, M.; Bollani, S.; Benvegnu, L.; Mazzella, G.; Ascione, A.; Santantonio, T.; Piccinino, F.; Andreone, P.; Mangia, A.; Gaeta, G. B.; Persico, M.; Fagiuoli, S.; Almasio, P. L. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology, 2007, 45(3), 579-587.
16. Borgia, G.; Reynaud, L.; Gentile, I.; Borrelli, F.; Cerini, R.; Ciampi, R.; Piazza, M. Pernicious anemia during IFN-alpha treatment for chronic hepatitis C. J. Interferon Cytokine Res., 2003, 23(1), 11-12.
17. Borgia, G.; Reynaud, L.; Gentile, I.; Cerini, R.; Ciampi, R.; Dello Russo, M.; Piazza, M. Myasthenia gravis during low-dose IFNalpha therapy for chronic hepatitis C. J. Interferon Cytokine Res., 2001, 21(7), 469-470.
18. Gentile, I.; Viola, C.; Reynaud, L.; Borrelli, F.; Cerini, R.; Ciampi, R.; Piazza, M.; Borgia, G. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J. Interferon Cytokine Res., 2005, 25(5), 283-285.
19. Hadziyannis, S. J.; Sette, H., Jr.; Morgan, T. R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer, H., Jr.; Bernstein, D.; Rizzetto, M.; Zeuzem, S.; Pockros, P. J.; Lin, A.; Ackrill, A. M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern Med., 2004, 140(5), 346-355.
20. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Goncales, F. L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl. J. Med., 2002, 347(13), 975-982.
21. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358(9286), 958-965.
22. Yoshida, T.; Kondoh, M.; Yagi, K. Promising targets for antihepatitis C virus agents. Curr. Med. Chem., 2011, 18(8), 1239-1244.
23. Carloni, G.; Crema, A.; Valli, M. B.; Ponzetto, A.; Clementi, M. HCV infection by cell-to-cell transmission: choice or necessity? Curr. Mol. Med., 2012, 12(1), 83-95.
24. Sofia, M. J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.; Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang, P.; Zhang, H. R.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.; Steuer, H. M.; Niu, C.; Otto, M. J.; Furman, P. A. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C- methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem., 2010, 53(19), 7202-7218.
25. Simmonds, P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol., 2004, 85(Pt 11), 3173-3188.
26. Gentile, I.; Viola, C.; Borgia, F.; Castaldo, G.; Borgia, G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr. Med. Chem., 2009, 16(9), 1115-1121.
27. Parfieniuk, A.; Jaroszewicz, J.; Flisiak, R., Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol., 2007, 13(43), 5673-81.
28. Martell, M.; Esteban, J. I.; Quer, J.; Genesca, J.; Weiner, A.; Esteban, R.; Guardia, J.; Gomez, J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol., 1992, 66(5), 3225-3229.
29. Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol., 2006, 299, 261-284.
30. Lam, A. M.; Espiritu, C.; Bansal, S.; Micolochick Steuer, H. M.; Niu, C.; Zennou, V.; Keilman, M.; Zhu, Y.; Lan, S.; Otto, M. J.; Furman, P. A. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother., 2012, 56(6), 3359-3368.
31. Rodriguez-Torres, M.; Lawitz, E.; Kowdley, K. V.; Nelson, D. R.; Dejesus, E.; McHutchison, J. G.; Cornpropst, M. T.; Mader, M.; Albanis, E.; Jiang, D.; Hebner, C. M.; Symonds, W. T.; Berrey, M. M.; Lalezari, J. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J. Hepatol., 2013, 58(4), 663-668.
32. Gane, E. J.; Stedman, C. A.; Hyland, R. H.; Ding, X.; Svarovskaia, E.; Symonds, W. T.; Hindes, R. G.; Berrey, M. M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl. J. Med., 2013, 368(1), 34-44.
33. Pockros, P. J. Nucleoside/Nucleotide analogue polymerase inhibitors in development. Clin. Liver Dis., 2013, 17(1), 105-110.
34. Lawitz, E. J.; Gruener, D.; Hill, J. M.; Marbury, T.; Moorehead, L.; Mathias, A.; Cheng, G.; Link, J. O.; Wong, K. A.; Mo, H.; McHutchison, J. G.; Brainard, D. M. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol., 2012, 57(1), 24-31.
35. Sciences, G. Press release: Gilead announces early sustained virologic response rates forGS-7977 plus ribavirin in genotype 1 treatment-naïve hepatitis C patients-interim results reported from ELECTRON and QUANTUM studies. http://www.gilead.com/pr-1757156 (accessed 19/02/2013).
36. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J. H.; O'Boyle, D. R., 2nd; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 2010, 465(7294), 96-100.
37. Fridell, R. A.; Qiu, D.; Wang, C.; Valera, L.; Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother., 2010, 54(9), 3641-3650.
38. Kuntzen, T.; Timm, J.; Berical, A.; Lennon, N.; Berlin, A. M.; Young, S. K.; Lee, B.; Heckerman, D.; Carlson, J.; Reyor, L. L.; Kleyman, M.; McMahon, C. M.; Birch, C.; Schulze Zur Wiesch, J.; Ledlie, T.; Koehrsen, M.; Kodira, C.; Roberts, A. D.; Lauer, G. M.; Rosen, H. R.; Bihl, F.; Cerny, A.; Spengler, U.; Liu, Z.; Kim, A. Y.; Xing, Y.; Schneidewind, A.; Madey, M. A.; Fleckenstein, J. F.; Park, V. M.; Galagan, J. E.; Nusbaum, C.; Walker, B. D.; Lake-Bakaar, G. V.; Daar, E. S.; Jacobson, I. M.; Gomperts, E. D.; Edlin, B. R.; Donfield, S. M.; Chung, R. T.; Talal, A. H.; Marion, T.; Birren, B. W.; Henn, M. R.; Allen, T. M. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology, 2008, 48(6), 1769-1778.